Teicoplanin antimicrobial-lock solution — Competitive Intelligence Brief

Teicoplanin antimicrobial-lock solution (Teicoplanin antimicrobial-lock solution) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Glycopeptide antibiotic. Area: Infectious Disease.

marketed Glycopeptide antibiotic Bacterial peptidoglycan (D-Ala-D-Ala) Infectious Disease Small molecule

Target snapshot

Teicoplanin antimicrobial-lock solution (Teicoplanin antimicrobial-lock solution) — Clinica Universidad de Navarra, Universidad de Navarra. Teicoplanin is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Teicoplanin antimicrobial-lock solution TARGET	Teicoplanin antimicrobial-lock solution	Clinica Universidad de Navarra, Universidad de Navarra	marketed	Glycopeptide antibiotic	Bacterial peptidoglycan (D-Ala-D-Ala)
Prophylactic Vancomycin	Prophylactic Vancomycin	Memorial Sloan Kettering Cancer Center	phase 3	Glycopeptide antibiotic	Bacterial peptidoglycan D-Ala-D-Ala precursors
Administration of Vancomycin	Administration of Vancomycin	University of Colorado, Denver	marketed	Glycopeptide antibiotic	D-Ala-D-Ala peptidoglycan precursor
Vancomycin with Taper/Pulse	Vancomycin with Taper/Pulse	VA Office of Research and Development	marketed	Glycopeptide antibiotic	Bacterial peptidoglycan (D-Ala-D-Ala)
Oritavancin Injection	Oritavancin Injection	University of Pennsylvania	marketed	Lipoglycopeptide antibiotic	Bacterial peptidoglycan precursors (D-Ala-D-Ala) and lipid II
Vancomycin intermittent dosing interval	Vancomycin intermittent dosing interval	Massachusetts General Hospital	marketed	Glycopeptide antibiotic	Bacterial peptidoglycan (D-Ala-D-Ala)
Vancomycin CI	Vancomycin CI	Wake Forest University Health Sciences	marketed	Glycopeptide antibiotic	D-Ala-D-Ala peptidoglycan precursor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Glycopeptide antibiotic class)

1. Clinica Universidad de Navarra, Universidad de Navarra · 2 drugs in this class
2. Memorial Sloan Kettering Cancer Center · 2 drugs in this class
3. Wake Forest University Health Sciences · 2 drugs in this class
4. VA Office of Research and Development · 1 drug in this class
5. Merck Sharp & Dohme LLC · 1 drug in this class
6. Murdoch Childrens Research Institute · 1 drug in this class
7. OrthoCarolina Research Institute, Inc. · 1 drug in this class
8. University of Colorado, Denver · 1 drug in this class
9. University of Maryland, Baltimore · 1 drug in this class
10. Debiopharm International SA · 1 drug in this class